Skip to content

Phase II study of pemetrexed for advanced or relapsed non-squamous non-small-cell lung cancer in elderly patients

Phase II study of pemetrexed for advanced or relapsed non-squamous non-small-cell lung cancer in elderly patients - Phase II study of pemetrexed for advanced or relapsed non-squamous non-small-cell lung cancer in elderly patients

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004018
Enrollment
30
Registered
2010-08-10
Start date
2010-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous non-small cell lung cancer in elderly chemo-naive patients

Interventions

Sponsors

Juntendo University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically proven non-squamous non-small cell lung cancer 2)Chemo-naive clinical stage IIIB/IV or relapsed patients (no indication of surgery or radiotherapy) 3)Age of 70 years or older 4)Performance status(PS) of 0-1 in ECOG criteria 5)Adequate organ functions 6)With measurable lesion 7)Life expectancy more than 3 months 8)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients with brain metastasis in need of steroid or anticonvulsant 2)Previous radiation therapy to primary lesion 3)History of active double cancer 4)Patients with superior vena cava syndrome 5)Uncontrollable pleural effusion, pericardial effusion or ascites 6)History of uncontrollable hypertention, diabetes mellitus, active angina pectoris, active gastrointestinal hemorrhage, recent cardiac incompetence, recent myocardial infarction, and active virus infection(except viral hepatitis) 7)Interstitial pneumonia or pulmonary fibrosis obviously detectable on chest X-ray 8)History of severe drug allergy 9)History of severe psychiatric disease 10)Patients whose participation in the trial is judged to be inappropriate by the attending doctor

Design outcomes

Primary

MeasureTime frame
Response rate

Secondary

MeasureTime frame
Overall survival Progression free survival Safety Quality of life

Countries

Japan

Contacts

Public ContactKeiko Muraki

Juntendo University, School of Medicine Department of Respiratory Medicine

03-5802-1063

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026